BRAF and colon adenocarcinoma: Previously, we found significantly increased abundance of cytoplasmic p-NPM1 (Thr199) in tumour tissue from BRAF-mutated in comparison with wild-type BRAF colon adenocarcinoma patients and demonstrated the role of p-NPM1 (Thr199) in mediating the resistance to vemurafenib in BRAF mutant colon cancer cells [16].